Mitsubishi Tanabe Pharma Corporation http://www.mt-pharma.co.jp/e/ en [Topics] Annual Report 2010 http://www.mt-pharma.co.jp/e/release/topics.php#201008300000151 Mon, 30 Aug 2010 00:00:00 +0900 [News Release] Completes Post-Marketing Surveillance on All Patients withRefractory Uveoretinitis in Behcet's DiseaseREMICADE I.V. Drip Infusion Anti-TNFα Monoclonal Antibody 100 http://www.mt-pharma.co.jp/e/release/index.php#20100818000098 Wed, 18 Aug 2010 00:00:00 +0900 [Topics] Conference Call for FY2010 1st Quarter Business Results [Q&A〕 http://www.mt-pharma.co.jp/e/release/topics.php#201008020000150 Mon, 02 Aug 2010 00:00:00 +0900 [News Release] Selective β1 Receptor Blocker "Kerlong Tablets 5mg/10mg"Transfer of Manufacturing, Marketing, and Distribution Rights http://www.mt-pharma.co.jp/e/release/index.php#20100730000097 Fri, 30 Jul 2010 00:00:00 +0900 [News Release] Announcement of FY2010 1st Quarter Financial Results http://www.mt-pharma.co.jp/e/release/index.php#20100729000096 Thu, 29 Jul 2010 00:00:00 +0900 [News Release] Revision to First Half Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2011 http://www.mt-pharma.co.jp/e/release/index.php#20100729000095 Thu, 29 Jul 2010 00:00:00 +0900 [IR Calendar] Announcement of FY2010 1st Quater Financial Results http://www.mt-pharma.co.jp/e/ir/calendar.php#20100729000018 Thu, 29 Jul 2010 00:00:00 +0900 [Topics] Conference Call for FY2010 1st Quarter Business Results [Material][Audio] http://www.mt-pharma.co.jp/e/release/topics.php#201007290000149 Thu, 29 Jul 2010 00:00:00 +0900 [Investor Relations] Financial Results for FY2010 1Q【July 29, 2010】 http://www.mt-pharma.co.jp/e/ir/index.php#20100729000012 Thu, 29 Jul 2010 00:00:00 +0900 [News Release] Approval for Partial Changes in Indications, Dosage and Usage, as well as New 1000 mg Dosage Formulation, for Injectable New Quinolone Antibacterial Agents, Pasil and Pazucross http://www.mt-pharma.co.jp/e/release/index.php#20100723000094 Fri, 23 Jul 2010 00:00:00 +0900